Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate

NCT05647447 | Withdrawn Early Phase 1 FDA Drug

• 1 other identifier: STUDY00148766
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the preliminary efficacy of in reducing the frequency and severity of hot flashes in men on androgen deprivation therapy (ADT).

Conditions

Prostate Adenocarcinoma

Outcome Measures

Primary Outcomes (1)

• To evaluate the preliminary efficacy of in reducing the frequency and severity of vasomotor symptoms (VMS) in men on androgen deprivation therapy (ADT).

  Efficacy will be assessed using a composite outcome of median weekly hot flash frequency and severity at week 4 compared to baseline.

  28 days

Secondary Outcomes (9)

• To evaluate the effect of Osanetant on follicle stimulating hormone for men with prostate cancer on ADT.

  28 days

• To evaluate the effect of Osanetant on luteinizing hormone for men with prostate cancer on ADT.

  28 days

• To evaluate the effect of Osanetant on testosterone for men with prostate cancer on ADT.

  28 days

• To evaluate the effect of Osanetant on estradiol for men with prostate cancer on ADT.

  28 days

• Functional Assessment of Cancer Therapy-Prostate (FACT-P)

  28 days

Study Arms (1)

Pilot Trial: Osanetant 28 Days

EXPERIMENTAL

Osanetant 200 mg orally, twice per day for 28 days.

Drug: Osanetant

Interventions

Osanetant DRUG

Osanetant 200 mg orally, twice per day

Pilot Trial: Osanetant 28 Days

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
• Males ≥ 18 years
• Histologic diagnosis of prostate cancer (PCa)
• Undergoing active treatment with ADT within ≥ 30 days prior to randomization
• Using either an gonadotropin releasing hormone (GNRH) agonist with a planned duration covering the 8 weeks of the study or are status post bilateral orchiectomy,
• Have a castrate level of testosterone (≤ 50 ng/dL) at enrollment
• Have moderate-to-severe hot flashes defined as
• Seven (7) or more hot flashes per day
• Total hot flash severity (HFS: total number of hot flashes for 1 week multiplied by the average severity/week) ≥ 100
• Adequate organ function, defined as follows: Result Date
• Leukocytes \> 1.5K/UL
• Absolute Neutrophil Count (ANC) \>1.5K/UL NOTE: Patients with established diagnosis of benign neutropenia are eligible to participate with ANC between 1000-1500 if in the opinion of treating physician the trial treatment does not pose excessive risk of infection to the patient.
• Platelets \>100K/UL
• Hemoglobin ≥ 9 g/dL
• Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault equation

You may not qualify if:

• Concurrent invasive malignancy or invasive malignancy within 2 years except for chronic lymphocytic leukemia/small lymphocytic lymphoma on surveillance, suspected or proven clinical stage 1 (cT1) renal cell carcinoma on active surveillance, or the following malignancies treated with curative intent via surgical resection: carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, low-grade non-muscle-invasive urothelial carcinoma, non-melanoma skin cancer.
• Simultaneously enrolled in any therapeutic clinical trial
• Current or anticipating use of other pharmacologic anti-neoplastic (including hormonal), or investigational agents while participating in this study. Concurrent treatment with radiotherapy is permitted.
• Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements
• Has a known allergic reaction to any excipient contained in the study drug formulation
• Active Grade 3 (per the NCI CTCAE, Version 5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment.
• Participants using the following medications within 2 weeks prior to first dosing (or within 5 times the half-life of that medication, whichever is longer) will be excluded from the study:
• Inhibitors of CYP3A4 (including but not limited to macrolide antibiotics, HIV protease inhibitor, azole antifungal drugs, cyclosporine, calcium channel inhibitor, cimetidine)
• Inducers of CYP3A4 (including but not limited to rifampicin, carbamazepine, efavirenz, bosentan, modafinil, St. John's Wort), Medications with narrow therapeutic index that are metabolized CYP3A4 and/or CYP2D6 are not allowed from screening until up to 5 half-lives after last dose of Osanetant is administered.

Sponsors & Collaborators

• University of Kansas Medical Center: lead

Study Sites (1)

The University of Kansas Cancer Center, Westwood Campus

Kansas City, Kansas, 66205, United States

Location

MeSH Terms

Interventions

SR 142801

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Single-arm pilot

Study Record Dates

• First Submitted: November 1, 2022
• First Posted: December 12, 2022
• Study Start: January 3, 2023
• Primary Completion: September 22, 2023
• Study Completion: October 5, 2023
• Last Updated: February 21, 2024

Record last verified: 2024-02

Locations

US (1)